Renal Denervation: A Treatment for Hypertension and Chronic Kidney Disease

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Renal sympathetic overactivity contributes to the development and progression of hypertension and chronic kidney disease (CKD).1–3 Conversely, progressive decline in renal function can exacerbate sympathetic overactivity.4,5 Renal denervation (RDN) in experimental models of hypertension and CKD has been shown to reduce blood pressure (BP) and improve renal function, which laid the foundation for the introduction of RDN to clinical practice.6 Although the efficacy of RDN as a treatment for hypertension has been disputed, the majority of data suggest that there is a place for RDN in the clinic and trials are ongoing (Table).
Original languageEnglish
Pages (from-to)528-536
Number of pages9
JournalHypertension
Volume72
Issue number3
DOIs
Publication statusPublished - 1 Sep 2018

Cite this

@article{55bffbf22812408a8b3462b3d647d19e,
title = "Renal Denervation: A Treatment for Hypertension and Chronic Kidney Disease",
abstract = "Renal sympathetic overactivity contributes to the development and progression of hypertension and chronic kidney disease (CKD).1–3 Conversely, progressive decline in renal function can exacerbate sympathetic overactivity.4,5 Renal denervation (RDN) in experimental models of hypertension and CKD has been shown to reduce blood pressure (BP) and improve renal function, which laid the foundation for the introduction of RDN to clinical practice.6 Although the efficacy of RDN as a treatment for hypertension has been disputed, the majority of data suggest that there is a place for RDN in the clinic and trials are ongoing (Table).",
author = "Singh, {Reetu R.} and Denton, {Kate M.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.118.10265",
language = "English",
volume = "72",
pages = "528--536",
journal = "Hypertension",
issn = "0194-911X",
publisher = "American Heart Association",
number = "3",

}

Renal Denervation : A Treatment for Hypertension and Chronic Kidney Disease. / Singh, Reetu R.; Denton, Kate M.

In: Hypertension, Vol. 72, No. 3, 01.09.2018, p. 528-536.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Renal Denervation

T2 - A Treatment for Hypertension and Chronic Kidney Disease

AU - Singh, Reetu R.

AU - Denton, Kate M.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Renal sympathetic overactivity contributes to the development and progression of hypertension and chronic kidney disease (CKD).1–3 Conversely, progressive decline in renal function can exacerbate sympathetic overactivity.4,5 Renal denervation (RDN) in experimental models of hypertension and CKD has been shown to reduce blood pressure (BP) and improve renal function, which laid the foundation for the introduction of RDN to clinical practice.6 Although the efficacy of RDN as a treatment for hypertension has been disputed, the majority of data suggest that there is a place for RDN in the clinic and trials are ongoing (Table).

AB - Renal sympathetic overactivity contributes to the development and progression of hypertension and chronic kidney disease (CKD).1–3 Conversely, progressive decline in renal function can exacerbate sympathetic overactivity.4,5 Renal denervation (RDN) in experimental models of hypertension and CKD has been shown to reduce blood pressure (BP) and improve renal function, which laid the foundation for the introduction of RDN to clinical practice.6 Although the efficacy of RDN as a treatment for hypertension has been disputed, the majority of data suggest that there is a place for RDN in the clinic and trials are ongoing (Table).

UR - http://www.scopus.com/inward/record.url?scp=85055609275&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.118.10265

DO - 10.1161/HYPERTENSIONAHA.118.10265

M3 - Article

C2 - 30354761

AN - SCOPUS:85055609275

VL - 72

SP - 528

EP - 536

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 3

ER -